satralizumab: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
satralizumab: clinical details
Prescribing considerations
- Confirm AQP4-IgG seropositivity and specialist-established NMOSD diagnosis.
- Ensure active infections are controlled and review immunisation status before initiation.
- Provide the patient alert card and training in infection recognition and injection technique.
- Record the product name and batch number to maintain biological traceability.
- Clinical evidence in adolescents is limited compared with adults.
Contraindications and cautions
- Hypersensitivity to satralizumab or any excipient.
- Delay administration during active infection; interrupt and assess serious or opportunistic infection.
- Avoid concurrent live or live-attenuated vaccines.
- Use caution where liver dysfunction, neutropenia or thrombocytopenia develops.
Monitoring
- Monitor ALT and AST early in treatment and periodically thereafter; follow product-specific interruption or discontinuation criteria for significant abnormalities.
- Check neutrophil counts after initiation and subsequently when clinically indicated.
- Assess platelet counts and bilirubin where clinically indicated.
- Remain vigilant for infection even when inflammatory markers are low; IL-6 blockade reduces CRP pharmacodynamically.
Clinical pharmacology
A recombinant humanised IgG2 monoclonal antibody that binds soluble and membrane-bound IL-6 receptors, preventing downstream signalling. Clearance includes linear and target-mediated pathways, and effects on CYP substrate handling may persist after treatment stops.
Formulation and product differences
- The selected UK product is a colourless to slightly yellow solution supplied in a single-use pre-filled syringe with an automatic needle guard.
- It requires refrigerated storage, protection from light and moisture, and must not be frozen. Limited unrefrigerated storage is permitted under the conditions specified in the product information.
satralizumab preparations and strengths
Injection
Route: Parenteral
Strengths: 120 mg
satralizumab interactions
Formal interaction studies have not been performed. Tell the prescriber about all medicines and planned vaccinations.
Warfarin, carbamazepine, phenytoin and theophylline
Starting or stopping satralizumab may alter CYP-mediated clearance, so clinical or laboratory monitoring and adjustment may be required.
Live or live-attenuated vaccines
These should not be given concurrently because safety with satralizumab has not been established; vaccination status should be reviewed before treatment.
Azathioprine, oral corticosteroids and mycophenolate mofetil
Population analyses did not identify an effect on satralizumab clearance, and these medicines may form part of specialist combination therapy.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.